About the Company
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology.
Employees
44
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NEXI News
NexImmune, Inc. (7370.F)
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by ...
NexImmune Secures Funding Through Equity and Warrant Sales
NexImmune, Inc. has struck a deal with a healthcare-focused institutional investor to sell over 117,000 shares and pre-funded ...
NexImmune, Inc. (NEXI) Stock Historical Prices & Data - Yahoo Finance
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
NexImmune Inc Ordinary Shares NEXI
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
NexImmune, Inc. (NEXI) stock price, news, quote & history – Yahoo Finance
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by ...
Why Yext Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
NexImmune, Inc. (NASDAQ: NEXI) shares dropped 13.3% to $0.2990 in pre-market trading after dropping over 5% on Tuesday. NexImmune recently presented initial data from NEXI-001 Phase 1 trial for ...
NexImmune Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsight
As per DelveInsight analysis, the Acute Myeloid Leukemia market is anticipated to witness growth at a considerable CAGR.
NexImmune, Inc. (NEXI) Latest Stock News & Headlines - Yahoo Finance
NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NexImmune Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo Finance
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by ...
NexImmune, Inc. (NEXI) stock historical prices & data – Yahoo Finance
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...